Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.
American University of the Caribbean, Cupecoy, Netherland Antilles.
Heart Rhythm. 2016 Feb;13(2):407-15. doi: 10.1016/j.hrthm.2015.10.016. Epub 2015 Oct 9.
Adenosine can reveal dormant pulmonary vein (PV) conduction after PV isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). However, the impact of elimination of adenosine-provoked dormant PV conduction after PVI has not been formally evaluated.
The purpose of this study was to determine whether ablation of PV reconnections unmasked by adenosine improves outcomes.
Patients with paroxysmal AF (n = 129) were randomized to receive either adenosine (n = 61) or no adenosine (n = 68) after PVI. Dormant conduction revealed by adenosine after PVI was ablated until all adenosine-mediated reconnections were eliminated. Thereafter, both groups received isoproterenol.
Acute reconnection was seen in 23 patients (37%) in the adenosine group. There was a significant difference between the number of PVs reconnected if patients were given adenosine >60 minutes after initial PVI compared to those who received adenosine <60 minutes after initial PVI (3/32 [9.4%] vs 24/32 [75%], P <.0001). Patients who did not receive adenosine had more PV reconnections after isoproterenol infusion compared to patients in the adenosine group (17/68 [25.0%] vs 5/61 [8.2%], P = .018). There was no difference in the rate of AF recurrence in patients who received adenosine (24/61 [39%]) compared to control patients (23/68 [34%], log-rank P = .83).
Adenosine can reveal dormant conduction in more than one-third of patients with paroxysmal AF undergoing PVI. However, adenosine administration, and additional ablation of the resultant connections, does not improve long-term outcomes compared to a protocol that includes isoproterenol infusion.
腺苷可在阵发性心房颤动(AF)患者的肺静脉隔离(PVI)后揭示潜伏的肺静脉(PV)传导。然而,尚未正式评估 PVI 后消除腺苷诱发的潜伏 PV 传导的影响。
本研究的目的是确定消融由腺苷揭示的 PV 再连接是否可改善结果。
将 129 例阵发性 AF 患者随机分为腺苷组(n = 61)或无腺苷组(n = 68)。在 PVI 后给予腺苷或不给腺苷。消融 PVI 后由腺苷揭示的潜伏传导,直至消除所有腺苷介导的再连接。此后,两组均接受异丙肾上腺素。
腺苷组有 23 例(37%)患者出现急性再连接。与初始 PVI 后 60 分钟内接受腺苷的患者相比,初始 PVI 后 60 分钟内接受腺苷的患者 PV 再连接的数量有显著差异(3/32 [9.4%] vs 24/32 [75%],P <.0001)。与腺苷组患者相比,未接受腺苷的患者在异丙肾上腺素输注后 PV 再连接更多(17/68 [25.0%] vs 5/61 [8.2%],P =.018)。接受腺苷的患者(24/61 [39%])与对照组患者(23/68 [34%])的 AF 复发率无差异(对数秩 P =.83)。
在接受 PVI 的阵发性 AF 患者中,超过三分之一的患者可通过腺苷揭示潜伏性传导。然而,与包括异丙肾上腺素输注的方案相比,腺苷的给药和对由此产生的连接的额外消融并不能改善长期结果。